References 1.Aacute Rbara L
Baseline liver enzyme assessment is reasonable for patients with: Pre-existing liver disease or elevated baseline transaminases Metabolic syndrome or clinical features suggesting MASLD Concurrent use of other potentially hepatotoxic medications Obesity (BMI 30 kg/m) with additional metabolic risk factors History of excessive alcohol consumption For patients with abnormal baseline liver enzymes, periodic monitoring every 3-6 months during the first year of therapy allows clinicians to assess treatment response and detect any unexpected changes
Lyophilized glutathione is remarkably stable at room temperature for short periods, like during shipping
Notably, females account for about 70% of diagnosed cases, potentially due to estrogens influence on collagen metabolism and pain perception [5,6,7,8]
The 5-Amino 1MQ compound is engineered for researchers studying the intersection of sarcopenia and metabolic syndrome
Edaravone (Radicava) was approved by the FDA in 2017 to treat ALS patients (FDA 2017)
